Cantor Fitzgerald Reiterates Neutral Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “neutral” rating reiterated by stock analysts at Cantor Fitzgerald in a research note issued to investors on Monday, Benzinga reports. They presently have a $1,015.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential downside of 11.49% from the stock’s previous close.

Other equities analysts have also recently issued reports about the company. Piper Sandler upped their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research report on Friday, August 23rd. Wells Fargo & Company increased their price objective on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. TD Cowen lifted their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Truist Financial restated a “buy” rating and set a $1,200.00 target price (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. Finally, Argus lifted their price target on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,111.30.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $1,146.75 on Monday. The business has a fifty day moving average price of $1,128.09 and a 200-day moving average price of $1,028.93. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The company has a market capitalization of $126.36 billion, a PE ratio of 33.88, a PEG ratio of 3.97 and a beta of 0.12. Regeneron Pharmaceuticals has a 1-year low of $769.19 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. Regeneron Pharmaceuticals’s revenue was up 12.3% compared to the same quarter last year. During the same period last year, the business earned $8.79 EPS. As a group, equities analysts expect that Regeneron Pharmaceuticals will post 37.8 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Joseph J. Larosa sold 1,866 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the sale, the executive vice president now directly owns 37,937 shares in the company, valued at approximately $41,311,496.15. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,026 shares of company stock worth $11,498,705. 7.48% of the stock is owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. SteelPeak Wealth LLC increased its holdings in shares of Regeneron Pharmaceuticals by 173.0% in the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after purchasing an additional 692 shares during the last quarter. Atria Investments Inc raised its holdings in shares of Regeneron Pharmaceuticals by 12.2% during the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after acquiring an additional 941 shares in the last quarter. Nordea Investment Management AB boosted its position in shares of Regeneron Pharmaceuticals by 23.2% during the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock valued at $28,218,000 after acquiring an additional 5,495 shares during the last quarter. Tidal Investments LLC grew its holdings in shares of Regeneron Pharmaceuticals by 16.8% in the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after purchasing an additional 711 shares in the last quarter. Finally, Sierra Summit Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $1,011,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.